Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2015 8:07:42 GMT -5
With the slow roll launch that SNY is presenting us, complete with use of social media and discussion groups taking the place of advertising, couldn't MNKD just as easily have gone it alone and tripled their profits, or did they really need that up front payout.
|
|
|
Post by Chris-C on Apr 15, 2015 8:23:57 GMT -5
With the slow roll launch that SNY is presenting us, complete with use of social media and discussion groups taking the place of advertising, couldn't MNKD just as easily have gone it alone and tripled their profits, or did they really need that up front payout. Avogadro Here's my short answer, and I'll leave it to others on the board to add other points and explanations regarding the numerous complexities of launching a new pharmaceutical with global potential and points about business strategy in general. 1. MNKD needed the cash. 2 They have no experience in launches and no sales force. These are high complexity and high expense operations. MNKD wisely wanted a partner with a proven and experienced sales force and with a global presence (and strong reputation) in DM. 3. MNKD views itself (quite rightly) as more than a company with Afrezza (a potential blockbuster). It views Technosphere (its patented technology for conveniently inhaling drugs) as having many more therapeutic applications beyond diabetes, and it sees partnership and licensing arrangements as an appropriate business model for the long term success of the company. GLTA Chris C
|
|
|
Post by tripoley on Apr 15, 2015 8:33:04 GMT -5
With the slow roll launch that SNY is presenting us, complete with use of social media and discussion groups taking the place of advertising, couldn't MNKD just as easily have gone it alone and tripled their profits, or did they really need that up front payout. When SNY hits it hard you'll understand why we partnered with them. Right now I think they are figuring out the best way to market Afrezza and how it's doing with early adopters.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2015 8:39:21 GMT -5
You are only looking at the social media reviews but logistics is one of the main thing in business... imagine getting the product out to retail and insurance negotiations.. its better to leave it to the pros and Mannkind is anyways a development company
|
|
|
Post by mdcenter61 on Apr 15, 2015 8:42:49 GMT -5
Avo - given my confidence in management and investor relations right now, I think our attempt to "go it alone" would have been a keystone cops epic mess. I'm with Tripoley, I think SNY has a plan and will hit it hard once the initial data comes in and the kinks are worked out with manufacturing/distribution/insurance enrollment. Everything I have seen or at least read regarding feedback from early adopters has reinforced my faith in the science.
|
|
|
Post by bradleysbest on Apr 15, 2015 8:45:33 GMT -5
Frustrating share price & silence but I think once DTC begins everyone will be happy with SNY!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2015 9:09:09 GMT -5
With the slow roll launch that SNY is presenting us, complete with use of social media and discussion groups taking the place of advertising, couldn't MNKD just as easily have gone it alone and tripled their profits, or did they really need that up front payout. Avogadro Here's my short answer, and I'll leave it to others on the board to add other points and explanations regarding the numerous complexities of launching a new pharmaceutical with global potential and points about business strategy in general. 1. MNKD needed the cash. 2 They have no experience in launches and no sales force. These are high complexity and high expense operations. MNKD wisely wanted a partner with a proven and experienced sales force and with a global presence (and strong reputation) in DM. 3. MNKD views itself (quite rightly) as more than a company with Afrezza (a potential blockbuster). It views Technosphere (its patented technology for conveniently inhaling drugs) as having many more therapeutic applications beyond diabetes, and it sees partnership and licensing arrangements as an appropriate business model for the long term success of the company. GLTA Chris C That's how they did it in the olden times . Today whole countries rise and fall, political ideas are promoted even new musical groups go viral on the power of social media and YouTube. I don't like it, but that's the way it is.
|
|
|
Post by gomnkd on Apr 15, 2015 9:19:09 GMT -5
MNKD was left with Hobson's choice. SNY had MNKD by its balls. IF we went alone, mgmt would have happily offered a non-dilutive financing of another 1/2 billion shares to setup offices coast to coast, ramp up HR, build a sales force from scratch (not to mention layers of VP), train them, build rapport with docs (read sandwiches, cruise tickets), build marketing team, buy ad space, conduct ph4 trials....
Also Palumbo will be HR head of a global organization and be burdened with lots of options.
Adam F would bemoan missing the glory days when MNKD had puny debt and only 400MM shares outstanding.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2015 9:26:50 GMT -5
That's how they did it in the olden times . Today whole countries rise and fall, political ideas are promoted even new musical groups go viral on the power of social media and YouTube. I don't like it, but that's the way it is. This is a drug....inhaled through lungs.. so people might be skeptical and would need assurance by doctors...so not exactly the same thing
|
|
|
Post by ezrasfund on Apr 15, 2015 10:06:42 GMT -5
Another point about the slow launch is that the trials, and therefore the label, do not show the benefits of Afrezza. Faster acting than RAA's? Less hypoglycemia? Better HbA1c? With the slow launch we have the early adopters demonstrating the real potential of Afrezza when used with the proper dosing protocols. While these benefits cannot be specifically claimed by SNY or MNKD, doctors and patients can spread the word about their experiences, which seem to be very positive and even well beyond what was expected by everyone but Al.
|
|
|
Post by cjc04 on Apr 15, 2015 10:19:24 GMT -5
You are only looking at the social media reviews but logistics is one of the main thing in business... imagine getting the product out to retail and insurance negotiations.. its better to leave it to the pros and Mannkind is anyways a development company I think you nailed it!!! SNY is the biggest and best at marketing & distribution for diabetes, in the world. To think MNKD could've done this is a joke. There are A LOT of bugs being worked out as we speak, and SNY is the most capable to work them out. The biggest one I see is insurance. Yes, the social media feed back is just about all positive for A, however, there are a lot of stories about fighting insurance co's to get their scripts covered, especially because they're all trying to figure out dosing and most are going over....., these are the things that need to be worked out in a slow launch. Can anyone imagine a massive push, tens of thousands of scripts being written, and then they're all fighting ins co's on dosages...... In that scenario, the social media would be a mess and not favorable to us.
|
|
|
Post by jimo on Apr 15, 2015 11:43:27 GMT -5
I think the biggest challenge is Sanofi's focus - which none of us really know. What we do know is they have a new CEO that is faced with immediately preserving the Lantus revenue of almost $7B from 2014. If he doesn't do that as job 1 they are in trouble. www.statista.com/statistics/266506/sanofi-top-pharmaceutical-products/It's much more important for Sanofi & easier for their reps to teach a doc about something they already know about - injecting daily insulin with a pen, nothing new here. They are pitching the ease of transition and benefits of Toujeo over daily injectables including Lantus. Doc says "I get it" and starts writing scripts. With Afrezza we have education, spirometry, dosing, unnecessary lung concerns and insurance hurdles to clear and this takes time. Sanofi can't replace at-risk Lantus revenue with Afrezza yet as that took years to build and unfortunately for us will take years to build with Afrezza. I'm not sure when the big push comes but we need it.
|
|
|
Post by jpg on Apr 15, 2015 12:26:42 GMT -5
I would say the first big push is starting. End users like it and say it is transformational. When is the last time you heard someone say that about an diabetic product: the introduction of pens maybe? And barely?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2015 12:47:15 GMT -5
cjc, your observations about all the bugs of a new product launch not to mention a revolutionary new product launch are spot on. For the insurance thing, I read one user suggesting to another user to have their doc write for the Rx in units vs days supply as this method resolved the issues, problems and delays from their insurance company. Lots of little things like this take time to learn about and to spread the word.
SNY knows what they are doing. Call it a soft launch or whatever suits your fancy, SNY is still laying much needed ground work before they can do a full blown launch. Once all these bugs are worked out and the KOLs have been trained and are on board and lines 2&3 are good to go, things will start to accelerate.
Dumping fuel into the engine too quickly causes it to stall...
|
|
|
Post by cjc04 on Apr 15, 2015 13:21:50 GMT -5
cjc, your observations about all the bugs of a new product launch not to mention a revolutionary new product launch are spot on. For the insurance thing, I read one user suggesting to another user to have their doc write for the Rx in units vs days supply as this method resolved the issues, problems and delays from their insurance company. Lots of little things like this take time to learn about and to spread the word. SNY knows what they are doing. Call it a soft launch or whatever suits your fancy, SNY is still laying much needed ground work before they can do a full blown launch. Once all these bugs are worked out and the KOLs have been trained and are on board and lines 2&3 are good to go, things will start to accelerate. Dumping fuel into the engine too quickly causes it to stall... Thx Scotta,,,,, I completely agree with you as well... Call it a slow/soft launch, or what ever makes ya feel good. As far as I'm concerned it's an in house trial.... Work out the ins. Issues, let patients work on real life dosing vs. the limitations of the FDA trials, distribution, education, and build inventory.... SNY knows what they're doing and I'm fine with the silence. In fact, I'm really starting to wonder if the 12 unit cartridge is needed more than realized. If so, will a full blown launch be delayed until it's approved, inventory built, and real world tested too? Hope we're not waiting that long, but if that's what it takes, so be it..... I'm not going anywhere.
|
|